Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug mevidalen aims to ease Alzheimer's symptoms in 300-Person trial

NCT ID NCT06538116

Symptom relief Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug mevidalen can safely improve thinking, memory, and daily function in people with mild-to-moderate Alzheimer's disease. About 300 participants will receive either mevidalen or a placebo for 26 weeks. The main goal is to see if the drug eases symptoms like confusion and difficulty with everyday tasks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

304 people

The number who actually took part.

Started

Aug 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * Have MMSE score of 13 to 24. * Have eligibile plasma P-tau or historical evidence of AD pathology. * Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times. * Males with partners of childbearing potential must agree to abide with provided contraception guidance. Exclusion Criteria: * Are individuals of childbearing potential. * Have significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,). * Have cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities. * Use of moderate or strong CYP3A4 inhibitors or inducers. * Have participated within the last 30 days in a clinical trial involving an investigational product. * Participant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • AMC Research, LLC dba Flourish Research

    Matthews, North Carolina, 28105, United States

  • Accel Research Sites - NeuroStudies CRU

    Decatur, Georgia, 30030, United States

  • ActivMed Practices & Research, LLC

    Methuen, Massachusetts, 01844, United States

  • Akita City Hospital

    Akita, 010-0933, Japan

  • Ascension Alexian Brothers

    Elk Grove Village, Illinois, 60007, United States

  • Banner Alzheimer's Institute

    Phoenix, Arizona, 85006, United States

  • Baptist Health Center for Clinical Research LLC

    Little Rock, Arkansas, 72205, United States

  • Be Well Clinical Studies

    Round Rock, Texas, 78681, United States

  • Brain Matters Research

    Stuart, Florida, 34997, United States

  • California Neuroscience Research, LLC

    Sherman Oaks, California, 91403, United States

  • Catalina Research Institute

    Montclair, California, 91763, United States

  • Cedar Health Research, LLC

    Euless, Texas, 76040, United States

  • CenExel Advanced Memory Research Institute of NJ

    Toms River, New Jersey, 08755, United States

  • CenExel iResearch Atlanta

    Decatur, Georgia, 30030, United States

  • CenExel iResearch, LLC

    Savannah, Georgia, 31405, United States

  • Charter Research - The Villages

    The Villages, Florida, 32162, United States

  • Charter Research, LLC

    Orlando, Florida, 32803, United States

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32256, United States

  • Clinical Neuroscience Solutions, Inc.Ta

    Memphis, Tennessee, 38119, United States

  • Clinical Trial Network LLC

    Houston, Texas, 77074, United States

  • Clinical Trials of Texas, LLC San Antonio dba Flourish Research

    San Antonio, Texas, 78229, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • El Faro Health and Therapeutics

    Rio Grande City, Texas, 78582, United States

  • Excel Medical Clinical Trials, LLC Boca Raton dba Flourish Research

    Boca Raton, Florida, 33434, United States

  • Eximia Clinical Research-NC, LLC

    Raleigh, North Carolina, 27612, United States

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii, 96817, United States

  • Himeji Central Hospital Clinic

    Himeji-shi, 672-8043, Japan

  • Ikuseikai Shinozuka Hospital

    Fujioka-shi, 375-0017, Japan

  • Inage Neurology and Memory Clinic

    Chiba, 263-0043, Japan

  • Intercoastal Medical Group

    Sarasota, Florida, 34239, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • Josephson, Wallack, Munshower Neurology, P.C.

    Indianapolis, Indiana, 46256, United States

  • Katayama Medical Clinic

    Kurashiki-shi, 710-0813, Japan

  • Kerwin Medical Center

    Dallas, Texas, 75231, United States

  • Keystone Clinical Studies, LLC Philadelphia dba Flourish Research

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Kishikai Kishi Hospital

    Kiryu-shi, 376-0011, Japan

  • Koseikai Cocoro Hospital Kusatsu

    Hiroshima, 733-0864, Japan

  • Kuramitsu Hospital

    Fukuoka, 819-0037, Japan

  • Mabashi Clinic

    Matsudo-shi, 271-0047, Japan

  • Memory Clinic Ochanomizu

    Bunkyō City, 113-0034, Japan

  • Memory Clinic Toride

    Toride-shi, 302-0004, Japan

  • Mental Clinic Sakurazaka

    Fukuoka, 810-0023, Japan

  • Merritt Island Medical Research, LLC dba Flourish Research

    Merritt Island, Florida, 32952, United States

  • NHO Hizen Psychiatric Medical Center

    Kanzaki-gun, 842-0192, Japan

  • National Center for Geriatrics and Gerontology

    Obu-shi, 474-8511, Japan

  • Neuropain Medical Center

    Fresno, California, 93710, United States

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida, 33912, United States

  • Oita University Hospital

    Yufu-shi, 879-5593, Japan

  • Premiere Research Institute at Palm Beach Neurology

    West Palm Beach, Florida, 33407, United States

  • Profound Research LLC At The Neurology Center of Southern California

    Carlsbad, California, 92011, United States

  • Progressive Medical Research

    Port Orange, Florida, 32127, United States

  • QUEST Research Institute

    Farmington Hills, Michigan, 48334, United States

  • Rainbow & Sea Hospital

    Karatsu-shi, 847-0031, Japan

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • Senior Adults Specialty Research

    Austin, Texas, 78757, United States

  • Southern TOHOKU Medical Clinic

    Koriyama-shi, 963-8563, Japan

  • Suncoast Clinical Research - New Port Richey

    New Port Richey, Florida, 34652, United States

  • Tokyo Medical University Hospital

    Shinjuku-ku, 160-0023, Japan

  • Tokyo Metropolitan Bokutoh Hospital

    Sumida-ku, 130-8575, Japan

  • University of Washington Medical Center

    Seattle, Washington, 98104, United States

  • Vertex Clinical Research

    Clermont, Florida, 34711, United States

  • Visionary Investigators Network

    Aventura, Florida, 33180, United States

  • Visionary Investigators Network

    Miami, Florida, 33176, United States

  • Yamagata University Hospital

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.